Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Axon Enterprise, Inc. (AXON), formerly Taser Intl. -- Ignore unavailable to you. Want to Upgrade?

To: John Carragher who wrote (467)	1/13/2005 10:58:46 AM
From: im a survivor	Read Replies (1) \| Respond to of 974

Taser Jumps on Safety Issue By TSC Staff 1/13/2005 8:45 AM EST Another day, another big swing in the shares of Taser International (TASR:Nasdaq - commentary - research) Shares in the stun gun maker surged Thursday after the Defense Department reportedly backed the safety and effectiveness of its stun guns. A Pentagon spokesman said Taser's public statements about a government study commissioned to test the safety of the devices accurately represented its conclusions, according to a report in The Wall Street Journal. The company Thursday also released details of a medical study that concluded its technology posed no cardiac risk. The Arizona-based company results published in the Pacing and Clinical Electrophysiology Journal concluded that the NMI electrical discharge from its guns showed "cardiac safety" and that the devices "may be safely applied multiple times if needed." Earlier this month, Taser disclosed an informal Securities and Exchange Commission inquiry into company statements about the safety of its stun guns and a recent order. Taser's guns have been the subject of rampant media controversy due to the number of people who have died after receiving shocks administered by police. The company says its guns were not responsible. Taser's weapons are used by about 6,000 law enforcement agencies around the world. Taser quoted the journal as saying the "devices have been empirically determined to maximize neuromuscular stimulation, cause pain and muscle contractions and temporarily incapacitate a human subject. Shares rose $4.29, or 25%, to $21.30 in premarket trading Thursday. Shares fell almost 30% on Tuesday after the company confirmed a round of recent insider selling and said competition could slow deliveries. The stock has been one of the market's best performers since 2002 but is down sharply this year, having closed at $31.65 on Dec. 31.